Spots Global Cancer Trial Database for lonafarnib
Every month we try and update this database with for lonafarnib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer | NCT00288444 | Lung Cancer Soft Tissue Sar... Colorectal Carc... Breast Cancer Prostate Cancer | Lonafarnib Docetaxel | - | Emory University | |
| Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer | NCT00281515 | Epithelial Ovar... | Lonafarnib | 18 Years - | AGO Study Group | |
| Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) | NCT00109538 | Myelodysplastic... Leukemia, Myelo... Myelodysplasia Myelomonocytic | Lonafarnib Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas | NCT00083096 | Brain and Centr... | lonafarnib temozolomide | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) | NCT00109538 | Myelodysplastic... Leukemia, Myelo... Myelodysplasia Myelomonocytic | Lonafarnib Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer | NCT00288444 | Lung Cancer Soft Tissue Sar... Colorectal Carc... Breast Cancer Prostate Cancer | Lonafarnib Docetaxel | - | Emory University | |
| Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide | NCT00102648 | Malignant Supra... Recurrent Gliob... Recurrent Glios... | Lonafarnib Temozolomide | 18 Years - | M.D. Anderson Cancer Center | |
| Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer | NCT00068757 | Breast Cancer | trastuzumab lonafarnib paclitaxel pharmacological... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Lonafarnib in Metastatic Breast Cancer | NCT00773474 | Metastatic Brea... | Lonafarnib | 18 Years - | Hoosier Cancer Research Network | |
| SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract | NCT00006351 | Bladder Cancer Transitional Ce... Urethral Cancer | gemcitabine hyd... lonafarnib | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) | NCT00109538 | Myelodysplastic... Leukemia, Myelo... Myelodysplasia Myelomonocytic | Lonafarnib Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Lonafarnib in Metastatic Breast Cancer | NCT00773474 | Metastatic Brea... | Lonafarnib | 18 Years - | Hoosier Cancer Research Network | |
| SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer | NCT00020774 | Liver Cancer | gemcitabine hyd... lonafarnib conventional su... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas | NCT00083096 | Brain and Centr... | lonafarnib temozolomide | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
